Tunicamycin, puromycin and brefeldin A influence the subcellular distribution of neuropeptides in hypothalamic magnocellular neurones of rat.
Magnocellular neurones in the supraoptic nuclei of normal Long Evans and homozygous Brattleboro rats were examined electron-microscopically after intracisternal injections of tunicamycin, puromycin, or brefeldin A. Moderate (50 micrograms) or high (200 micrograms) doses of tunicamycin caused the formation of electron-dense filamentous accretions in the endoplasmic reticulum (ER) cisterns of vasopressin neurones, but only the high dose of tunicamycin also caused accretions to form in the ER of some oxytocin neurones. Immunogold labelling of ultrathin sections from tunicamycin-treated rats revealed that, in about 5% of vasopressin neurones, the accretions could be immunogold-labelled for vasopressin and its associated neurophysin. However, in the majority of vasopressin neurones, the sections required trypsinisation before immunolabelling of the accretions could be detected. Small accretions in the ER of oxytocin neurones did not label for oxytocin or its neurophysin without prior trypsinisation, whereas larger accretions in other oxytocin cells could be labelled without prior trypsin treatment. Administration of puromycin resulted in the formation of small ER accretions in both vasopressin and oxytocin neurones. These accretions were immunolabelled with antisera, respectively, to vasopressin and oxytocin, but neurophysin-immunoreactivity was in most cases absent and was not revealed by treatment with trypsin, suggesting that neurophysin-immunoreactive epitopes were absent from truncated peptides forming the accretions. Brefeldin A caused dilatation of ER cisterns and disruption of the Golgi apparatus in both oxytocin and vasopressin neurones, but did not cause accretions to form in the ER.
Pow
D V
DV
Department of Human Anatomy, University of Oxford, UK.
Morris
J F
JF
D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D020126:Brefeldin A; D003517:Cyclopentanes / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D004721:Endoplasmic Reticulum / Q000737:chemistry / Q000648:ultrastructure; D006056:Golgi Apparatus / Q000648:ultrastructure; D007031:Hypothalamus / Q000737:chemistry* / Q000378:metabolism / Q000648:ultrastructure; D008854:Microscopy, Electron; D008928:Mitochondria / Q000648:ultrastructure; D009474:Neurons / Q000737:chemistry* / Q000378:metabolism / Q000648:ultrastructure; D009479:Neuropeptides / Q000032:analysis* / Q000378:metabolism; D010121:Oxytocin / Q000032:analysis; D011691:Puromycin / Q000494:pharmacology*; D051381:Rats; D011913:Rats, Inbred BB; D014415:Tunicamycin / Q000494:pharmacology*; D014667:Vasopressins / Q000032:analysis
D000900:Anti-Bacterial Agents; D003517:Cyclopentanes; D009479:Neuropeptides; D014667:Vasopressins; D014415:Tunicamycin; D020126:Brefeldin A; D011691:Puromycin; D010121:Oxytocin